ARTICLE | Company News
Atrix submits 3-month leuprogel NDA
September 26, 2001 7:00 AM UTC
ATRX submitted an NDA to the FDA for leuprogel leuprolide acetate three-month depot to treat advanced prostate cancer. ATRX submitted an NDA for its leuprogel one-month depot product earlier this year...